Table 3.
Odds ratios for postmenopausal breast cancer by polymorphisms in the vitamin D receptor gene
| Genotype | Cases | Controls | Crude modela | Adjusted modelb | |||||
| n | % | n | % | OR (95% CI) | OR (95% CI) | Pc | |||
| TaqI | 1,403 | 2,609 | 0.33 | ||||||
| TT | 497 | 35.4 | 980 | 37.6 | 1 | 1 | |||
| Tt | 667 | 47.6 | 1,218 | 46.7 | 1.08 | (0.94–1.25) | 1.08 | (0.93–1.26) | |
| tt | 239 | 17.0 | 411 | 15.7 | 1.15 | (0.95–1.39) | 1.11 | (0.91–1.36) | |
| Tt/tt | 1.10 | (0.96–1.26) | 1.09 | (0.95–1.26) | |||||
| FokI | 1,390 | 2,596 | 0.24 | ||||||
| FF | 566 | 40.7 | 998 | 38.5 | 1 | 1 | |||
| Ff | 606 | 43.6 | 1,203 | 46.3 | 0.88 | (0.77–1.02) | 0.89 | (0.77–1.03) | |
| ff | 218 | 15.7 | 395 | 15.2 | 0.98 | (0.80–1.19) | 0.97 | (0.79–1.19) | |
| Ff/ff | 0.91 | (0.80–1.04) | 0.91 | (0.79–1.05) | |||||
| VDR-5132 | 1,400 | 2,607 | 0.92 | ||||||
| CC | 488 | 34.9 | 892 | 34.2 | 1 | 1 | |||
| CT | 683 | 48.8 | 1,284 | 49.3 | 0.99 | (0.85–1.14) | 1.00 | (0.86–1.16) | |
| TT | 229 | 16.3 | 431 | 16.5 | 0.99 | (0.81–1.20) | 1.01 | (0.83–1.24) | |
| CT/TT | 0.99 | (0.86–1.13) | 1.00 | (0.87–1.16) | |||||
| Cdx2 | 1,406 | 2,606 | 0.22 | ||||||
| GG | 888 | 63.1 | 1,701 | 65.3 | 1 | 1 | |||
| GA | 465 | 33.1 | 795 | 30.5 | 1.11 | (0.97–1.28) | 1.08 | (0.94–1.25) | |
| AA | 53 | 3.8 | 110 | 4.2 | 0.94 | (0.67–1.32) | 0.94 | (0.66–1.33) | |
| GA/AA | 1.09 | (0.95–1.25) | 1.07 | (0.93–1.23) | |||||
aConditional logistic regression stratified by year of birth. bConditional logistic regression stratified by year of birth adjusted for age at menopause, first-degree family history of breast cancer, history of benign breast disease, number of pregnancies (≥28th week), age at menarche, breastfeeding history, total number of mammograms, use of hormone therapy, body mass index, education level and smoking status. cχ2 test for difference between cases and controls comparing the three genotypes for each polymorphism. CI, confidence interval; OR, odds ratio.